Literature DB >> 30796154

Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without Helicobacter pylori Infection.

Wen-Liang Fang1,2, Kuo-Hung Huang3,2, Shih-Ching Chang4,2, Chien-Hsing Lin5, Ming-Huang Chen6,2, Yee Chao6,2, Su-Shun Lo2,7, Anna Fen-Yau Li8,2, Chew-Wun Wu3,2, Yi-Ming Shyr3,2.   

Abstract

BACKGROUND: Helicobacter pylori (HP) can induce epithelial cells and intestinal metaplasia with genetic damage that makes them highly susceptible to the development of gastric cancer (GC).
MATERIALS AND METHODS: Between 2005 and 2010, 356 patients with gastric cancer who received curative surgery were enrolled. Analysis of HP, Epstein-Barr virus (EBV) infection, PIK3CA amplification, and mutation analysis of 68 mutations in eight genes using a mass spectrometric single-nucleotide polymorphism genotyping technology was conducted. The clinicopathological characteristics of patients with or without HP infection were compared.
RESULTS: Among the 356 patients, 185 (52.0%) had HP infection. For intestinal-type GC, patients with HP infection were more likely to be younger and had fewer PI3K/AKT pathway genetic mutations than those without HP infection. For diffuse-type GC, patients with HP infection were characterized by less male predominance, less lymphoid stroma, fewer microsatellite instability-high tumors, and fewer PI3K/AKT pathway genetic mutations than those without HP infection. Patients with HP infection had less tumor recurrence and a better 5-year overall survival (87.7% vs. 73.9%, p = .012) and disease-free survival (64.1% vs. 51.3%, p = .013) than those without HP infection, especially for intestinal-type GC. For EBV-negative GC, patients with HP infection had fewer PI3K/AKT pathway mutations and a better 5-year overall survival and disease-free survival than those without HP infection. Multivariate analysis demonstrated that HP infection was an independent prognostic factor regarding overall survival and disease-free survival.
CONCLUSION: Patients with GC with HP infection were associated with fewer PI3K/AKT pathway genetic mutations and better survival than those without HP infection, especially for EBV-negative and intestinal-type GC. IMPLICATIONS FOR PRACTICE: Patients with gastric cancer with Helicobacter pylori (HP) infection had fewer PI3K/AKT pathway genetic mutations, less tumor recurrence, and better survival than those without HP infection, especially for Epstein-Barr virus (EBV)-negative and intestinal-type gastric cancer. HP infection is an independent prognostic factor regarding overall survival and disease-free survival. Future in vivo and in vitro studies of the correlation among HP infection, PI3K/AKT pathway, and EBV infection in gastric cancer are required. © AlphaMed Press 2019.

Entities:  

Keywords:  zzm321990Helicobacter pylori; Diffuse‐type; Epstein‐Barr virus; Intestinal‐type; Prognostic factor

Year:  2019        PMID: 30796154      PMCID: PMC6738298          DOI: 10.1634/theoncologist.2018-0742

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  36 in total

1.  Risk of subsequent development of gastric cancer in patients with previous gastric epithelial neoplasia.

Authors:  T Aoi; H Marusawa; T Sato; T Chiba; M Maruyama
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

Review 2.  Helicobacter pylori eradication and associated changes in the gastric mucosa.

Authors:  Kazunari Murakami; Masaaki Kodama; Ryugo Sato; Tadayoshi Okimoto; Koichiro Watanabe; Toshio Fujioka
Journal:  Expert Rev Anti Infect Ther       Date:  2005-10       Impact factor: 5.091

3.  Helicobacter pylori infection and the development of gastric cancer.

Authors:  N Uemura; S Okamoto; S Yamamoto; N Matsumura; S Yamaguchi; M Yamakido; K Taniyama; N Sasaki; R J Schlemper
Journal:  N Engl J Med       Date:  2001-09-13       Impact factor: 91.245

4.  Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium.

Authors:  Yuko Matsumoto; Hiroyuki Marusawa; Kazuo Kinoshita; Yoko Endo; Tadayuki Kou; Toshiyuki Morisawa; Takeshi Azuma; Il-Mi Okazaki; Tasuku Honjo; Tsutomu Chiba
Journal:  Nat Med       Date:  2007-04-01       Impact factor: 53.440

5.  Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma.

Authors:  Julie L Ryan; Hongxin Fan; Sally L Glaser; Steven A Schichman; Nancy Raab-Traub; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

Review 6.  Detection of Helicobacter pylori in faeces by culture, PCR and enzyme immunoassay.

Authors:  S Kabir
Journal:  J Med Microbiol       Date:  2001-12       Impact factor: 2.472

7.  Relationship between genetic alterations and prognosis in sporadic colorectal cancer.

Authors:  Shih-Ching Chang; Jen-Kou Lin; Shung Haur Yang; Huann-Sheng Wang; Anna Fen-Yau Li; Chin-Wen Chi
Journal:  Int J Cancer       Date:  2006-04-01       Impact factor: 7.396

8.  Better survival of Helicobacter pylori infected patients with early gastric cancer is related to a higher level of Thomsen-Friedenreich antigen-specific antibodies.

Authors:  Oleg Kurtenkov; Kersti Klaamas; Boris Sergeyev; Valentin Chuzmarov; Ljudmila Miljukhina; Ljudmila Shljapnikova
Journal:  Immunol Invest       Date:  2003-02       Impact factor: 3.657

9.  Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.

Authors:  Benjamin Chun-Yu Wong; Shiu Kum Lam; Wai Man Wong; Jian Shun Chen; Ting Ting Zheng; Rui E Feng; Kam Chuen Lai; Wayne Hsing Cheng Hu; Siu Tsan Yuen; Suet Yi Leung; Daniel Yee Tak Fong; Joanna Ho; Chi Kong Ching; Jun Shi Chen
Journal:  JAMA       Date:  2004-01-14       Impact factor: 56.272

10.  Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study.

Authors:  Georgios Meimarakis; Hauke Winter; Ilka Assmann; Reinhard Kopp; Norbert Lehn; Manfred Kist; Manfred Stolte; Kalter-Walter Jauch; Rudolf A Hatz
Journal:  Lancet Oncol       Date:  2006-03       Impact factor: 41.316

View more
  6 in total

1.  Racial/ethnic differences in survival among gastric cancer patients in california.

Authors:  Amy K Klapheke; Luis G Carvajal-Carmona; Rosemary D Cress
Journal:  Cancer Causes Control       Date:  2019-05-17       Impact factor: 2.506

2.  Genetic alterations in gastric cancer patients according to sex.

Authors:  Li-Wen Hsu; Kuo-Hung Huang; Ming-Huang Chen; Wen-Liang Fang; Yee Chao; Su-Shun Lo; Anna Fen-Yau Li; Chew-Wun Wu; Yi-Ming Shyr
Journal:  Aging (Albany NY)       Date:  2020-12-03       Impact factor: 5.682

Review 3.  Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis.

Authors:  Zhifang Jia; Min Zheng; Jing Jiang; Donghui Cao; Yanhua Wu; Yuzheng Zhang; Yingli Fu; Xueyuan Cao
Journal:  BMC Cancer       Date:  2022-02-08       Impact factor: 4.430

4.  The Clinicopathological Features and Genetic Alterations in Epstein-Barr Virus-Associated Gastric Cancer Patients after Curative Surgery.

Authors:  Wen-Liang Fang; Ming-Huang Chen; Kuo-Hung Huang; Chien-Hsing Lin; Yee Chao; Su-Shun Lo; Anna Fen-Yau Li; Chew-Wun Wu; Yi-Ming Shyr
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639

5.  Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array.

Authors:  Wen-Liang Fang; Ming-Huang Chen; Kuo-Hung Huang; Shih-Ching Chang; Chien-Hsing Lin; Yee Chao; Su-Shun Lo; Anna Fen-Yau Li; Chew-Wun Wu; Yi-Ming Shyr
Journal:  Clin Epigenetics       Date:  2019-11-01       Impact factor: 6.551

6.  Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification.

Authors:  Shih-Min Pai; Kuo-Hung Huang; Ming-Huang Chen; Wen-Liang Fang; Yee Chao; Su-Shun Lo; Anna Fen-Yau Li; Chew-Wun Wu; Yi-Ming Shyr
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.